Literature DB >> 28126452

Early sepsis bundle compliance for non-hypotensive patients with intermediate versus severe hyperlactemia.

Daniel E Leisman1, Jason A Zemmel D'Amore2, Jeanie L Gribben2, Mary Frances Ward3, Kevin D Masick4, Andrea R Bianculli2, Kathryn H Bradburn2, John K D'Angelo2, Martin E Doerfler5.   

Abstract

OBJECTIVE: To compare the association of 3-h sepsis bundle compliance with hospital mortality in non-hypotensive sepsis patients with intermediate versus severe hyperlactemia.
METHODS: This was a cohort study of all non-hypotensive, hyperlactemic sepsis patients captured in a prospective quality-improvement database, treated October 2014 to September 2015 at five tertiary-care centers. We defined sepsis as 1) infection, 2) ≥2 SIRS criteria, and 3) ≥1 organ dysfunction criterion. "Time-zero" was the first time a patient met all sepsis criteria. INCLUSION CRITERIA: systolic blood pressure>90 mmHg, mean arterial pressure>65 mmHg, and serum lactate≥2.2 mmol/L. Primary exposures: 1) intermediate(2.2-3.9 mmol/L) versus severe(≥4.0 mmol/L) hyperlactemia and 2) full 3-h bundle compliance. Bundle elements: The primary outcome was 60-day in-hospital mortality.
RESULTS: 2417 patients met inclusion criteria. 704(29%) had lactate≥4.0 mmol/L versus 1775 patients with lactate 2.2-3.9 mmol/L. Compliance was 75% for antibiotics and 53% for fluids. Full-compliance was comparable between lactate groups (n=200(29%) and 488(28%), respectively). We observed 424(17.5%) mortalities: intermediate/non-compliant - 182(14.9%), intermediate/compliant - 41(8.4%), severe/non-compliant - 147(29.2%), severe/compliant - 54(27.0%) [difference-of-differences=4.3%, CI=2.6-5.9%]. In multivariable regression, mortality predictors included severe hyperlactemia (OR=1.99, CI=1.51-2.63) and bundle compliance (OR=0.62, CI=0.42-0.90), and their interaction was significant: p(interaction)=0.022.
CONCLUSION: We observed a significant interaction between 3-h bundle compliance and initial hyperlactemia. Bundle compliance may be associated with greater mortality benefit for non-hypotensive sepsis patients with less severe hyperlactemia.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28126452     DOI: 10.1016/j.ajem.2017.01.029

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

1.  Effect of Systematic Physician Cross-checking on Reducing Adverse Events in the Emergency Department: The CHARMED Cluster Randomized Trial.

Authors:  Yonathan Freund; Hélène Goulet; Judith Leblanc; Jérôme Bokobza; Patrick Ray; Maxime Maignan; Sabine Guinemer; Jennifer Truchot; Anne-Laure Féral-Pierssens; Youri Yordanov; Anne-Laure Philippon; Edwin Rouff; Ben Bloom; Marine Cachanado; Alexandra Rousseau; Tabassome Simon; Bruno Riou
Journal:  JAMA Intern Med       Date:  2018-06-01       Impact factor: 21.873

2.  An investigation of sepsis surveillance and emergency treatment on patient mortality outcomes: An observational cohort study.

Authors:  Robert C Amland; Bharat B Sutariya
Journal:  JAMIA Open       Date:  2018-05-15

3.  Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs.

Authors:  Karin Thursky; Senthil Lingaratnam; Jasveer Jayarajan; Gabrielle M Haeusler; Benjamin Teh; Michelle Tew; Georgina Venn; Alison Hiong; Christine Brown; Vivian Leung; Leon J Worth; Kim Dalziel; Monica A Slavin
Journal:  BMJ Open Qual       Date:  2018-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.